Hepatic encephalopathy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:18:27 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hepatic encephalopathy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of VS-01 with different treatment times compared to standard care alone in patients with overt hepatic encephalopathy and liver cirrhosis complications https://clinicaltrials.eu/trial/study-of-vs-01-with-different-treatment-times-compared-to-standard-care-alone-in-patients-with-overt-hepatic-encephalopathy-and-liver-cirrhosis-complications/ Wed, 29 Apr 2026 15:06:50 +0000 https://clinicaltrials.eu/trial/study-of-vs-01-with-different-treatment-times-compared-to-standard-care-alone-in-patients-with-overt-hepatic-encephalopathy-and-liver-cirrhosis-complications/ This study focuses on patients with overt hepatic encephalopathy, a condition that affects brain function due to advanced liver disease. The condition occurs in people who have liver cirrhosis with sudden worsening of symptoms or acute complications. The study will test a new investigational medicine called VS-01, which is given as a suspension through the abdominal cavity, in addition to regular standard treatment.

The purpose of this research is to determine if VS-01 can help treat overt hepatic encephalopathy when given once daily for up to 4 days. The study will compare two different treatment durations (3 hours and 4 hours) of VS-01 combined with standard care against standard care alone. The medication contains citric acid as its main component and is administered through intraperitoneal delivery, which means it is given directly into the abdominal cavity.

During the study, patients will receive either VS-01 with standard treatment or standard treatment alone. The treatment period lasts up to 4 days, during which doctors will monitor how quickly patients’ symptoms improve. The study will also look at how the body processes the medication and track any changes in blood and abdominal fluid composition to ensure the treatment is safe.

]]> Study on Rifaximin for Delaying Hepatic Encephalopathy in Cirrhosis Patients https://clinicaltrials.eu/trial/study-on-rifaximin-for-delaying-hepatic-encephalopathy-in-cirrhosis-patients/ Wed, 29 Apr 2026 14:23:37 +0000 https://clinicaltrials.eu/trial/study-on-rifaximin-for-delaying-hepatic-encephalopathy-in-cirrhosis-patients/ This clinical trial is focused on studying a condition known as Hepatic Encephalopathy, which is a complication that can occur in people with liver cirrhosis. The trial is investigating the use of a medication called Rifaximin, specifically in the form of 40 mg Soluble Solid Dispersion Immediate Release Tablets (SSD-40IR). The purpose of the study is to determine if Rifaximin can help delay the worsening of symptoms associated with this condition, which often leads to hospitalization.

Participants in the study will be randomly assigned to receive either the Rifaximin tablets or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are not biased. The study will take place over a period of time, during which participants will be monitored for any signs of their condition worsening, particularly those that might require hospitalization.

The main goal is to see how long it takes for participants to experience a significant event related to their condition, such as a hospitalization due to Hepatic Encephalopathy. The study will also look at other factors, such as the time it takes for any cause of hospitalization or serious health events to occur. This research aims to provide valuable information on the effectiveness and safety of Rifaximin in managing this serious liver-related condition.

]]>